IPO registrations (S-1, F-1) · Registrants
CDT Equity Inc.
- SEC CIK
- 1896212 · filings on EDGAR ↗
- Former names
- CONDUIT PHARMACEUTICALS INC. (2023–2025); Murphy Canyon Acquisition Corp. (2021–2023)
- Registration
- Form S-1, first filed 2022-01-06, last 2026-09-08; 4 initial registrations, 3 amendments
- Outcome
- Declared effective 2022-02-02; withdrawal requested 2022-01-26
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 4851 TAMIAMI TRAIL NORTH, SUITE 200, Naples, FL 34103
- EIN
- 87-3272543
- Ticker
- CDT, CDTTW (Nasdaq, Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- CDT Equity Inc. on the corporate pages
Offering terms
- Shares offered
- 16,825,644
- Listing
- Nasdaq under the symbol CDT
- Lead underwriters
- of Contents
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: CONDUIT PHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- SEC filer: CDT Equity Inc. EXACT (CIK (EXACT))
- Person page: Chele Chiavacci Farley Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 21
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2022-01-06 | S-1 | S-1 (registration) | Murphy Canyon Acquisition Corp. | 0001493152-22-000566 ↗ |
| 2022-01-26 | RW | RW (withdrawal request) | Murphy Canyon Acquisition Corp. | 0001493152-22-002218 ↗ |
| 2022-01-28 | S-1/A | S-1/A (amendment) | Murphy Canyon Acquisition Corp. | 0001493152-22-002595 ↗ |
| 2022-02-02 | EFFECT | EFFECT (declared effective) | Murphy Canyon Acquisition Corp. | 9999999995-22-000306 ↗ |
| 2023-08-11 | EFFECT | EFFECT (declared effective) | Murphy Canyon Acquisition Corp. | 9999999995-23-002356 ↗ |
| 2023-10-17 | S-1 | S-1 (registration) | CONDUIT PHARMACEUTICALS INC. | 0001493152-23-037514 ↗ |
| 2023-12-01 | S-1/A | S-1/A (amendment) | CONDUIT PHARMACEUTICALS INC. | 0001493152-23-043429 ↗ |
| 2023-12-15 | EFFECT | EFFECT (declared effective) | CONDUIT PHARMACEUTICALS INC. | 9999999995-23-003652 ↗ |
| 2024-05-02 | EFFECT | EFFECT (declared effective) | CONDUIT PHARMACEUTICALS INC. | 9999999995-24-001346 ↗ |
| 2024-09-04 | S-1 | S-1 (registration) | CONDUIT PHARMACEUTICALS INC. | 0001493152-24-034991 ↗ |
| 2024-09-13 | S-1/A | S-1/A (amendment) | CONDUIT PHARMACEUTICALS INC. | 0001493152-24-036199 ↗ |
| 2024-09-16 | EFFECT | EFFECT (declared effective) | CONDUIT PHARMACEUTICALS INC. | 9999999995-24-002854 ↗ |
| 2024-11-01 | EFFECT | EFFECT (declared effective) | CONDUIT PHARMACEUTICALS INC. | 9999999995-24-003346 ↗ |
| 2024-12-06 | EFFECT | EFFECT (declared effective) | CONDUIT PHARMACEUTICALS INC. | 9999999995-24-003695 ↗ |
| 2025-02-12 | EFFECT | EFFECT (declared effective) | CONDUIT PHARMACEUTICALS INC. | 9999999995-25-000429 ↗ |
| 2025-04-30 | EFFECT | EFFECT (declared effective) | CONDUIT PHARMACEUTICALS INC. | 9999999995-25-001314 ↗ |
| 2025-08-07 | EFFECT | EFFECT (declared effective) | CONDUIT PHARMACEUTICALS INC. | 9999999995-25-002523 ↗ |
| 2026-02-09 | EFFECT | EFFECT (declared effective) | CDT Equity Inc. | 9999999995-26-000486 ↗ |
| 2026-05-01 | EFFECT | EFFECT (declared effective) | CDT Equity Inc. | 9999999995-26-001441 ↗ |
| 2026-09-08 | S-1 | S-1 (registration) | CDT Equity Inc. | 0001493152-26-041808 ↗ |
| 2026-09-17 | EFFECT | EFFECT (declared effective) | CDT Equity Inc. | 9999999995-26-003001 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | S-1 | registration statement | 16,825,644 | - | Nasdaq CDT | 1 | primary document; shares headline, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bentzen Edwin H IV | Officer | Chief Accounting Officer | 1 | 2022 | |
| Farley Chele Chiavacci | Director | 10 | 2022–2026 | person page Fuzzy | |
| Feinberg Richard Edward | Director | 1 | 2022 | ||
| Francis Knuettel II | Director | 1 | 2022 | ||
| Heilbron Jack Kendrick | Director,Officer; Other | CEO, President, and Chairman | 2 | 2022–2023 | |
| Murphy Canyon Acquisition Sponsor, LLC | Other; TenPercentOwner | 2 | 2022–2023 | ||
| Sragovicz Adam | Director,Officer; Officer | CFO and Treasurer; Chief Financial Officer | 3 | 2022–2024 | |
| Shaolin Capital Management LLC | TenPercentOwner | 1 | 2023 | ||
| Algo Holdings, Inc. | TenPercentOwner; TenPercentOwner,Other | 2 | 2023–2024 | ||
| Bligh James | Director; Director,Officer | CFO; Interim CFO | 5 | 2023–2025 | |
| Charles Faith L. | Director | 6 | 2023–2025 | ||
| Corvus Capital Ltd. | TenPercentOwner; TenPercentOwner,Other | 4 | 2023–2025 | ||
| Intelmed LLC | Other | 2 | 2023–2024 | ||
| Lewis-Hall Freda C | Director | 7 | 2023–2025 | ||
| McNealey Jennifer Isacoff | Director | 3 | 2023–2024 | ||
| Regan Andrew | Director,Officer; Director,Officer,TenPercentOwner; Director,TenPercentOwner | Chief Executive Officer | 7 | 2023–2026 | |
| Tapolczay David | Director; Director,Officer | Chief Executive Officer | 4 | 2023–2024 | |
| Dovet Ltd | TenPercentOwner | 3 | 2024 | ||
| Nirland Ltd | TenPercentOwner | 3 | 2024 | ||
| Rowland Master Trust | TenPercentOwner | 3 | 2024 | ||
| Stockton Ltd | TenPercentOwner | 3 | 2024 | ||
| Fry Simon Jeremy | Director | 4 | 2024–2025 | ||
| Sarborg Ltd | TenPercentOwner | 1 | 2025 | ||
| Prospect Capital Securities Ltd | TenPercentOwner | 3 | 2026 | ||
| Prospect Finance Ltd | TenPercentOwner | 3 | 2026 | ||
| Taylor Mark Andrew | TenPercentOwner | 3 | 2026 | ||
| Olsen Ulrik K | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | CONDUIT PHARMACEUTICALS, INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| SEC filer | CDT Equity Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | CONDUIT PHARMACEUTICALS, INC. | EIN (EXACT) | ||
| Person page | Chele Chiavacci Farley | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, FL first:
- SANO CORP FL
- CTT PHARMACEUTICAL HOLDINGS, INC. FL
- Inhibitor Therapeutics, Inc. FL
- GENEREX BIOTECHNOLOGY CORP FL
- BIOMOLECULAR LIFE HOLDINGS, INC. FL
- Alaunos Therapeutics, Inc. FL
- ORAGENICS INC FL
- Polomar Health Services, Inc. FL
- ACCENTIA BIOPHARMACEUTICALS INC FL
- NOMAD POWER SOLUTIONS, INC. FL
In other datasets, the same topic (Health) in FL:
- Nonprofit: 414 WELLWOMEN INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health